National Lung Matrix Trial

The National Lung Matrix Trial is the largest precision medicine trial in non-small cell lung cancer globally, testing a wide-range of therapies tailored specifically to target key genetic changes in cancer cells.

Stratified Medicine Programme 2

Cancer Research UK’s Stratified Medicine Programme 2 provides national genomic pre-screening for patients with Non-Small Cell Lung cancer, and is required to determine patient molecular eligibility for the National Lung Matrix Trial.

Find out more

Also in 'National Lung Matrix Trial'

Latest videos

Gary Middleton - Precision Medicine Trials in Non-Small Cell Lung Cancer - PMWC UK 2015, Oxford

ESMO 2014: The ‘National Lung Matrix’ trial – a new strategy for cancer drug research

Latest news

Posted 17 December 2019

World Conference on Lung Cancer 2019

Posted 20 November 2017

16th June 2017, ECMC Announcement - SMP2 and NLMT programme updates

ECMC Announcement - SMP2 and NLMT programme updates

Posted 23 May 2017

CRUK Science Blog – Behind the scenes with the unsung heroes of cancer clinical trials – Part 4 (Interview with Jane Hair - Biobanker)

In this post, Jane Hair, a biobanker who works at the biorepository unit in Glasgow, and is involved in the National Lung Matrix Trial, shares what her job involves.